Conference
T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
Abstract
Antipsychotic (AP) medications are the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth and adolescent populations. However, APs have been associated with metabolic side effects including diabetes and obesity. Although several mechanisms have been proposed, the gut microbiome (GMB) has been suggested as a potential mediator of AP-induced metabolic side effects due to its role in weight …
Authors
Kanji S; Gorbovskaya I; Fonseka T; Yoshida K; Marshe V; MacKenzie M; Bercik P; Verdu E; Hahn M; Mueller D
Volume
44
Pagination
pp. s190-s191
Publisher
Oxford University Press (OUP)
Publication Date
April 1, 2018
DOI
10.1093/schbul/sby016.468
Conference proceedings
Schizophrenia Bulletin
Issue
suppl_1
ISSN
0586-7614